TY - JOUR
T1 - Prognostic significance of the labeling of Adnab-9 in pancreatic intraductal papillary mucinous neoplasms
AU - Tobi, Martin
AU - Hatfield, James
AU - Adsay, Volkan
AU - Galagan, Katherine
AU - Kozarek, Richard
AU - Inagaki, Mitsuhiro
AU - Kasai, Shinichi
AU - Tokusashi, Yoshihiko
AU - Obara, Takeshi
AU - Hruban, Ralph H.
AU - Lough, John
AU - Barkun, Alan N.
AU - Jabbari, Mansour
AU - Sheikh, Rafiq
AU - Ruebner, Boris
AU - Lawson, Michael J.
AU - Ben-Josef, Edgar
AU - Fligiel, Suzanne
PY - 2001/1/1
Y1 - 2001/1/1
N2 - Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p < 0.001) and 53% of adenomas (p < 0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.
AB - Background. Pancreatic intraductal papillary mucinous neoplasms (IPMN), morphologically resembling colonic adenomas, often have an indefinable malignant potential. We used a monoclonal antibody (MAb) raised against colonic adenomas, Adnab-9, to identify patients with a better prognosis. Methods. We assessed Adnab-9-labeled sections of these neoplasms from 50 patients, 13 pancreatic adenocarcinomas, and 32 colonic adenomas using standard immunohistochemical techniques. Results. 26% of the IPMNs labeled with Adnab-9 as compared to 0% of pancreatic ductal cancers or surrounding benign tissues, (p < 0.001) and 53% of adenomas (p < 0.025). Labeling in IPMNs was usually seen in the noninvasive epithelium suggesting that Adnab-9 is a premalignant marker in these lesions. Labeling of invasive IPMN's identified a group of patients with a superior overall survival (p = 0.027). Conclusion. Adnab-9 labeling-characteristics appear similar for both IPMNs and adenomatous polyps, suggesting that they are analogous lesions. Adnab-9 labeling may also be a useful prognostic marker for invasive intraductal papillary mucinous neoplasms.
KW - Colorectal cancer
KW - Immunostaining
KW - Intraductal papillary mucinous neoplasms
KW - Monoclonal antibody
KW - Pancreatic ductal cancer
KW - Severely dysplastic adenomatous colonic polyps
UR - http://www.scopus.com/inward/record.url?scp=0035739657&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035739657&partnerID=8YFLogxK
U2 - 10.1385/IJGC:29:3:141
DO - 10.1385/IJGC:29:3:141
M3 - Article
C2 - 12067217
AN - SCOPUS:0035739657
VL - 29
SP - 141
EP - 150
JO - Journal of Gastrointestinal Cancer
JF - Journal of Gastrointestinal Cancer
SN - 1941-6628
IS - 3
ER -